Eduard- Alexandru Bonci

Dr. Eduard- Alexandru Bonci

Iuliu Haţieganu University of Medicine and Pharmacy Cluj-Napoca
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Maggie Banys-PaluchowskiMaggie Banys-Paluchowski
Maggie Banys-Paluchowski
MGMaria Luisa Gasparri
Maria Luisa Gasparri
JBJana de Boniface
Jana de Boniface
Oreste D. GentiliniOreste D. Gentilini
Oreste D. Gentilini
ESElmar Stickeler
Elmar Stickeler
TGthe AXSANA Study Group
the AXSANA Study Group
In the last two decades, surgical methods for axillary staging in breast cancer patients have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the optimal management remains unclear. Current guidelines vary widely, endorsing different strategies. We performed a literature review on axillary staging strategies and their place in international recommendations. This overview defines knowledge gaps associated with specific procedures, summarizes currently ongoing clinical trials that address these unsolved issues, and provides the rationale for further research. While some guidelines have already implemented surgical de-escalation, replacing ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+ patients converting to clinical node negativity, others recommend ALND. Numerous techniques are in use for tagging lymph node metastasis, but many questions regarding the marking technique, i.e., the optimal time for marker placement and the number of marked nodes, remain unanswered. The optimal number of SLNs to be excised also remains a matter of debate. Data on oncological safety and quality of life following different staging procedures are lacking. These results provide the rationale for the multinational prospective cohort study AXSANA initiated by EUBREAST, which started enrollment in June 2020 and aims at recruiting 3000 patients in 20 countries (NCT04373655; Funded by AGO-B, Claudia von Schilling Foundation for Breast Cancer Research, AWOgyn, EndoMag, Mammotome, and MeritMedical).

29 June 2022 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MGMaria Luisa Gasparri
Maria Luisa Gasparri
JBJana de Boniface
Jana de Boniface
PPPhilip Poortmans
Philip Poortmans
OGOreste D Gentilini
Oreste D Gentilini
OKOrit Kaidar-Person
Orit Kaidar-Person
Thorsten KuehnThorsten Kuehn
Thorsten Kuehn
Background: There is no consensus on axillary management after neoadjuvant therapy (NAT) in patients with clinically node-positive (cN+) breast cancer. To investigate current clinical practice, an international survey was conducted among breast surgeons and radiation oncologists. The aim of the first part of the survey was to provide a snapshot of international discrepancies regarding axillary surgery in this context. Methods: The European Breast Cancer Research Association of Surgical Trialists (EUBREAST) developed a web-based survey containing 39 questions describing clinical scenarios in the setting of axillary management in patients with cN1 disease converting to ycN0 after NAT. The survey was then distributed to breast surgeons and radiation oncologists via 14 breast cancer societies between April and October 2021. Results: Responses from 349 physicians in 45 countries were recorded. The most common post-NAT axillary surgery in patients with cN1 disease converting to ycN0 was targeted axillary dissection (54.2 per cent), followed by sentinel lymph node biopsy (SLNB) alone (20.9 per cent), level 1–2 axillary lymph node dissection (ALND) (18.4 per cent), level 1–3 ALND (4 per cent), and targeted lymph node biopsy (2.5 per cent). For SLNB alone, dual tracers were most commonly used (62.3 per cent). Management varied widely in patients with ambiguous axillary status before initiation of treatment or a residual metastatic burden in the axilla after NAT. In patients with ycN+ tumours, ALND was the preferred surgical approach for 66.8 per cent of respondents. Conclusion: These results highlight the wide heterogeneity in surgical approaches to the axilla after NAT. To standardize the guidelines, further data from clinical research are urgently needed, which underlines the importance of the ongoing AXSANA (EUBREAST-3) study.

25 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LHLiviu Hitu
Liviu Hitu
KGKatalin Gabora
Katalin Gabora
EBEduard- Alexandru Bonci
Eduard- Alexandru Bonci
APAndra Piciu
Andra Piciu
AHAdriana-Cezara Hitu
Adriana-Cezara Hitu
DPDoina Piciu
Doina Piciu
The involvement of micro-ribonucleic acid (microRNAs) in metabolic pathways such as regulation, signal transduction, cell maintenance, and differentiation make them possible biomarkers and therapeutic targets. The purpose of this review is to summarize the information published in the last two and a half years about the involvement of microRNAs in papillary thyroid carcinoma (PTC). Another goal is to understand the perspective offered by the new findings. Main microRNA features such as origin, regulation, targeted genes, and metabolic pathways will be presented in this paper. We interrogated the PubMed database using several keywords: “microRNA” + “thyroid” + “papillary” + “carcinoma”. After applying search filters and inclusion criteria, a selection of 137 articles published between January 2018–June 2020 was made. Data regarding microRNA, metabolic pathways, gene/protein, and study utility were selected and included in the table and later discussed regarding the matter at hand. We found that most microRNAs regularly expressed in the normal thyroid gland are downregulated in PTC, indicating an important tumor-suppressor action by those microRNAs. Moreover, we showed that one gene can be targeted by several microRNAs and have nominally described these interactions. We have revealed which microRNAs can target several genes at once.

Verified
Journal Article
Open access
PDF file
TBTeodora Irina Adam Bonci
Teodora Irina Adam Bonci
EBEduard- Alexandru Bonci
Eduard- Alexandru Bonci
Alina Elena PârvuAlina Elena Pârvu
Alina Elena Pârvu
AHAndrei-Ioan Herdean
Andrei-Ioan Herdean
AMAugustin C. Moţ
Augustin C. Moţ
AIAlexandru Irimie
Alexandru Irimie
Asthma oxidative stress disturbances seem to enable supplementary proinflammatory pathways, thus contributing to disease development and severity. The current study analyzed the impact of two types of oral vitamin D (VD) supplementation regimens on the redox balance using a murine model of acute ovalbumin-induced (OVA-induced) asthmatic inflammation. The experimental prevention group received a long-term daily dose of 50 µg/kg (total dose of 1300 µg/kg), whereas the rescue group underwent a short-term daily dose of 100 µg/kg (total dose of 400 µg/kg). The following oxidative stress parameters were analyzed in serum, bronchoalveolar lavage fluid (BALF) and lung tissue homogenate (LTH): total oxidative status, total antioxidant response, oxidative stress index, malondialdehyde and total thiols. Results showed that VD significantly reduced oxidative forces and increased the antioxidant capacity in the serum and LTH of treated mice. There was no statistically significant difference between the two types of VD supplementation. VD also exhibited an anti-inflammatory effect in all treated mice, reducing nitric oxide formation in serum and the expression of nuclear factor kappa B p65 in the lung. In conclusion, VD supplementation seems to exhibit a protective role in oxidative stress processes related to OVA-induced acute airway inflammation.

7 October 2021 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
APAndrei Pașca
Andrei Pașca
EBEduard- Alexandru Bonci
Eduard- Alexandru Bonci
CCCodruța Chiuzan
Codruța Chiuzan
NJNicoleta Monica Jiboc
Nicoleta Monica Jiboc
VGVlad Alexandru Gâta
Vlad Alexandru Gâta
PAPatriciu Andrei Achimaș-Cadariu
Patriciu Andrei Achimaș-Cadariu
Background: Capsular contracture (CC) is the most common long-term complication of breast surgery with prosthesis. Leukotriene receptor antagonists (LRAs) have been tested as a potential treatment; however, mixed results have been observed. Objectives: The aim of this study was to undertake a meta-analysis to clarify the treatment and prophylactic capabilities of LRAs in the management of CC. Methods: A systematic literature search of the most popular English-language databases was performed to identify relevant primary publications. We included all studies that used the Baker scale to evaluate the treatment and preventive capabilities of LRAs. Results: Six eligible studies were included based on predefined inclusion and exclusion criteria, totalling 2276 breasts, of which 775 did not receive LRAs and 1501 did. Final pooled results showed that LRAs could help manage CC with a risk difference (RD) of –0.38 with a corresponding 95% CI of –0.69 to –0.08, showing statistical significance at a Z value of 2.48, P = 0.01. Subgroup analysis based on the type of drug showed that only montelukast yielded statistical significance (RD = –0.27, 95% CI = –0.51 to –0.03, Z = 2.20, P = 0.03). Zafirlukast did not seem to influence CC. Further subgroup analysis based on treatment timing showed that prophylaxis was ineffective and only treatment for ongoing CC yielded statistically significant improvements. Conclusions: The current meta-analysis proved that LRAs could be used in the management of CC. Only treatment for ongoing CC showed statistically significant improvements. Montelukast seemed to be more efficient with a safer profile for adverse effects, whereas zafirlukast yielded no statistically significant results. Level of Evidence: 4:

8 March 2020 in Mathematics
Verified
Journal Article
Open access
PDF file
LPLorand Gabriel Parajdi
Lorand Gabriel Parajdi
RPRadu Precup
Radu Precup
EBEduard- Alexandru Bonci
Eduard- Alexandru Bonci
CTCiprian Tomuleasa
Ciprian Tomuleasa
A mathematical model given by a two-dimensional differential system is introduced in order to understand the transition process from the normal hematopoiesis to the chronic and accelerated-acute stages in chronic myeloid leukemia. A previous model of Dingli and Michor is refined by introducing a new parameter in order to differentiate the bone marrow microenvironment sensitivities of normal and mutant stem cells. In the light of the new parameter, the system now has three distinct equilibria corresponding to the normal hematopoietic state, to the chronic state, and to the accelerated-acute phase of the disease. A characterization of the three hematopoietic states is obtained based on the stability analysis. Numerical simulations are included to illustrate the theoretical results.